BrightSpring Health Services (BTSG) Q3 2026 earnings summary

Executive summary

• Q3 continuing-operations revenue was $4,213.2M, up 26.4% YoY, and Adjusted EBITDA was $227.8M, up 42.0%; results exclude Community Living, divested March 30, 2026.

• Gross profit increased 32.3% to $518.5M; Pharmacy Solutions and Provider Services both grew revenue and Segment EBITDA, with Home Health Care revenue up 52.4%.

Financial highlights

• Q3 gross profit was $518.5M vs. $392.0M, and operating income was $160.5M vs. $87.8M.

• Net income from continuing operations was $100.8M vs. $37.5M; diluted EPS was $0.46 vs. $0.17 and Adjusted EPS was $0.54 vs. $0.30.

• 9M revenue was $11.700B, up 25% YoY; net income from continuing operations was $261.7M vs. $55.2M, and Adjusted EBITDA was $623.0M vs. $434.0M.

• Pharmacy Solutions gross profit was $316M, up 28.6% YoY; Provider Services gross profit was $203M, up 38.4%.

Outlook and guidance

• FY 2026 guidance increased to revenue of $15.900B–$16.125B and Adjusted EBITDA of $850M–$860M, excluding Community Living.

• Guidance implies revenue growth of 23.2%–24.9% and Adjusted EBITDA growth of 37.6%–39.3% vs. FY 2025 continuing operations.

• Guidance includes expected 2026 Adjusted EBITDA contribution of ~$35M from the Amedisys and LHC branches acquisition; segment revenue guidance is $14.0B–$14.2B for Pharmacy Solutions and $1.9B–$1.925B for Provider Services.